Full-Time

Assistant Vice President Digital Engineering

Posted on 9/10/2026

Deadline 12/31/26
CVS Health

CVS Health

10,001+ employees

Healthcare, insurance, PBM, and retail pharmacy

Compensation Overview

$185.4k - $375.9k/yr

+ Bonus + Commission + Short-term incentive + Equity award

Company Historically Provides H1B Sponsorship

Woonsocket, RI, USA

Remote

Bachelor's

Category
Engineering Management (1)
Required Skills
LLM
Flutter
Agile
React.js
Machine Learning
Data Engineering
Microservices
REST APIs
Web Development
HIPAA

Get referred to CVS Health

See people who can refer or advise you

Requirements
  • At least 15 years of software engineering experience, including at least 5 years in senior engineering leadership roles.
  • A proven track record delivering full-stack digital products at scale, ideally in health, benefits, insurance, or another regulated domain.
  • Deep experience leading large-scale, globally distributed teams and ensuring the health and stability of production operations.
  • Strong full-stack fluency across frontend technologies such as Flutter, React, and mobile platforms, backend APIs and microservices, and data layers.
  • Hands-on experience in agile delivery environments with short iteration cycles, pilot launches, and data-informed product development.
  • Experience managing the finances of large corporate portfolios and cost center expenses.
  • Technical expertise in triaging, understanding, and solving complex challenges across varied technology stacks, enterprise integrations, and vendor platforms.
  • Executive-level communication and influence skills, with hands-on or applied experience delivering artificial-intelligence-enabled or generative-artificial-intelligence-integrated software solutions.
  • A bachelor's degree.
Responsibilities
  • Own end-to-end engineering delivery for Health100's digital health solutions, including web, mobile, and backend services.
  • Drive an agile, iterative delivery model with short release cycles, tight feedback loops, and a pilot-first mindset.
  • Establish and maintain engineering standards for code quality, architecture, security, and scalability across the platform.
  • Define and evolve Health100's full-stack architecture, including member-facing application layers, artificial intelligence and machine learning integration, application programming interfaces, and data pipelines.
  • Partner with product and artificial intelligence leads to shape technical feasibility and roadmap sequencing, including artificial intelligence health assistant capabilities.
  • Embed Health Insurance Portability and Accountability Act compliance, protected health information handling, and security posture in the engineering process.
  • Lead internal individual contributors, engineering leaders, and external development vendors while holding all parties to unified delivery and quality standards.
  • Evaluate, onboard, and manage software development partners as strategic partners rather than staff augmentation.
  • Lead, mentor, and grow engineering managers and senior engineers while owning hiring, performance management, career development, succession planning, and a culture of accountability and high performance.
  • Create a culture of ownership, technical excellence, and proactive risk identification.
  • Serve as the senior engineering voice in product, strategy, and leadership forums by translating technical complexity into business clarity.
  • Own engineering metrics and reporting for Health100, including delivery velocity, platform reliability, artificial intelligence performance, and technical health.
  • Represent engineering in vendor negotiations, partner evaluations, and external technical due diligence.
Desired Qualifications
  • Experience building member-facing or patient-facing health applications and familiarity with Fast Healthcare Interoperability Resources, Health Level Seven, or health data standards.
  • Exposure to artificial intelligence and machine learning integration in production products, particularly conversational artificial intelligence or health artificial intelligence assistants.
  • Experience in a large enterprise health system, payer, or health technology company on the payer or provider side.
  • Experience leading digital enablement and transformative initiatives.

CVS Health operates as a diversified health services company in the United States, organized into Health Care Benefits, Pharmacy & Consumer Wellness, and Health Services. Its offerings include medical insurance products, retail and mail-order prescription drugs, and pharmacy benefit management (PBM) services, all connected through its integrated platform. By combining insurance, retail pharmacy, PBM, and health solutions, CVS Health coordinates care and controls costs across touchpoints for individuals, employers, and government programs. The company aims to lower health care costs while improving access and health outcomes for customers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Woonsocket, Rhode Island

Founded

1963

Get referred to CVS Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 5, 2026 CVS raised adjusted EPS guidance to $7.90-$8.10 and revenue to $414 billion.
  • Walgreens plans roughly 1,200 U.S. store closures through 2027, sending prescription volume to CVS.
  • Teresa Heitsenrether joined the board September 2026, strengthening CVS’s data and digital execution focus.

What critics are saying

  • May 2026 340B lawsuits from Mount Sinai, Michigan, and Kansas attack Caremark’s remittance model.
  • CVS disclosed 2027 Caremark membership declines and continued 340B pressure on August 5, 2026.
  • If courts restrict 340B spreads or rebate flows, CVS loses a core profit engine.

What makes CVS Health unique

  • CVS Health combines Aetna, Caremark, and 9,000 pharmacies across one U.S. customer funnel.
  • August 5, 2026 results showed integrated pricing, insurance, and pharmacy scale outperformed standalone peers.
  • The August 2026 Eli Lilly collaboration embeds Zepbound and Foundayo access inside CVS channels.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

Company Equity

Wellness Program

Professional Development Budget

Paid Vacation

Paid Holidays

Company News

Yahoo Finance
Sep 14th, 2026
CVS Health up 32% in a year: is it time to buy the stock?

CVS Health shares have declined 2.1% over the past three months, prompting investors to consider whether now is an opportune time to buy. The healthcare giant, which operates approximately 9,000 retail pharmacy locations and serves more than 35 million people through its health insurance business, reported second-quarter revenue of $106 billion, up 7.3% year-over-year. Adjusted earnings per share rose 43% in the same period. The company offers a dividend yield of 2.8%, with its annual payout increasing from $2 in 2021 to $2.66 per share recently. Shares currently trade at $95, with one analyst setting a price target of $120. The stock's forward price-to-earnings ratio of 11 sits slightly above its five-year average of 10.

Yahoo Finance
Sep 13th, 2026
US health insurers rebound as medical costs stabilise, analysts predict 16% earnings growth through 2030

The health insurance industry may have recovered from high medical costs, with analysts predicting strong growth through 2030. Morningstar forecasts 16% annual earnings per share growth for major insurers, above the industry's typical low-double-digit target. Health insurers are improving profitability by raising rates to cover increased medical utilisation. UnitedHealth Group reported over $5 billion in second-quarter net income, with its medical care ratio falling to 86.7% from 89.4% year-over-year. The outlook also improved for pharmacy benefit management operations at companies like UnitedHealth, CVS Health, and Cigna. Despite increased regulatory scrutiny, the "big three" PBMs maintain strong competitive positions. Third-quarter earnings reports next month should provide further clarity on the industry's financial health.

Yahoo Finance
Sep 12th, 2026
CVS quietly gains market share as Walgreens closes 1,200 US stores following $10B private equity sale

Walgreens is closing roughly 1,200 of its approximately 8,500 US locations through 2027, with many customers being redirected to nearby CVS pharmacies. The pattern is reshaping suburban pharmacy markets without direct competition. In August 2025, Walgreens completed a $10 billion sale to private equity firm Sycamore Partners, taking the 124-year-old chain private for the first time. Mike Motz was named chief executive, replacing Tim Wentworth. CVS is gaining market share without active expansion efforts. Federal and state rules require orderly prescription transfers when pharmacies close, often directing patients to the nearest CVS location. CVS and Walgreens together now handle nearly 40% of all US retail prescription sales. CVS benefits from owning Caremark, a dominant pharmacy benefit manager, providing vertical integration advantages.

Yahoo Finance
Aug 28th, 2026
CVS stock down 12% in a month despite 34% annual gain, faces 2027 headwinds

CVS Health stock has declined 12.3% over the past month, sitting about 15% below its 52-week high, though it remains up 34% over the trailing twelve months. The company's revenue reached approximately $415 billion, up 7.4% year-over-year. Management raised its full-year 2026 adjusted earnings per share guidance by $0.60 to a range of $7.90 to $8.10. For 2027, the company anticipates membership declines at Caremark and continued 340B programme pressure, offset by Aetna's recovery, which added over $2 billion in adjusted operating income in the first half of 2026. Management considers a 2027 adjusted EPS outlook of at least $8.44 reasonable. Historically, CVS has experienced varied recovery periods following market downturns, with some rebounds taking years rather than months.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.